Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy

The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided by the RS result are lacking. We performed explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stemmer, Salomon M., Steiner, Mariana, Rizel, Shulamith, Ben-Baruch, Noa, Uziely, Beatrice, Jakubowski, Debbie M., Baron, Julie, Shak, Steven, Soussan-Gutman, Lior, Bareket-Samish, Avital, Fried, Georgeta, Rosengarten, Ora, Itay, Amit, Nisenbaum, Bella, Katz, Daniela, Leviov, Michelle, Tokar, Margarita, Liebermann, Nicky, Geffen, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841708/
https://www.ncbi.nlm.nih.gov/pubmed/31728408
http://dx.doi.org/10.1038/s41523-019-0137-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6841708/
https://www.ncbi.nlm.nih.gov/pubmed/31728408
http://dx.doi.org/10.1038/s41523-019-0137-3

Ejemplares similares